Abstract
AbstractEffectively designing and evaluating public health responses to the ongoing COVID-19 pandemic requires accurate estimation of the prevalence of COVID-19 across the United States (US). Equipment shortages and varying testing capabilities have however hindered the usefulness of the official reported positive COVID-19 case counts. We introduce four complementary approaches to estimate the cumulative incidence of symptomatic COVID-19 in each state in the US as well as Puerto Rico and the District of Columbia, using a combination of excess influenza-like illness reports, COVID-19 test statistics, COVID-19 mortality reports, and a spatially structured epidemic model. Instead of relying on the estimate from a single data source or method that may be biased, we provide multiple estimates, each relying on different assumptions and data sources. Across our four approaches emerges the consistent conclusion that on April 4, 2020, the estimated case count was 5 to 50 times higher than the official positive test counts across the different states. Nationally, our estimates of COVID-19 symptomatic cases as of April 4 have a likely range of 2.2 to 4.9 million, with possibly as many as 8.1 million cases, up to 26 times greater than the cumulative confirmed cases of about 311,000. Extending our method to May 16, 2020, we estimate that cumulative symptomatic incidence ranges from 6.0 to 10.3 million, as opposed to 1.5 million positive test counts. The proposed combination of approaches may prove useful in assessing the burden of COVID-19 during resurgences in the US and other countries with comparable surveillance systems.
Publisher
Cold Spring Harbor Laboratory
Reference75 articles.
1. World Health Organization. Report of the who-china joint mission on coronavirus disease 2019.
2. Centers for Disease Control and Prevention. Locations with confirmed covid-19 cases.
3. Marc Lipsitch and Mauricio Santillana . Enhancing situational awareness to prevent infectious disease outbreaks from becoming catastrophic. Global Catastrophic Biological Risks, pages 59–74, 2019.
4. Sheila Kaplan Sheri Fink Katie Thomas Michael D. Shear , Abby Goodnough and Noah Weiland . The lost month: How a failure to test blinded the u.s. to covid-19.
5. Arjun K. Manrai and Kenneth D. Mandl . Covid-19 testing: overcoming challenges in the next phase of the epidemic.
Cited by
43 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献